QS
Qin, S.
2 papers · 5 citations · 2023–2023
Publications
2
Citations
5
Years
1
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
|
2023 | Meeting Abstract | 0 |
|
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
|
2023 | Meeting Abstract | 5 |